Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LT3001 in Acute Ischemic Stroke Undergoing EVT
NCT05198323Phase 2Active, not recruiting
- Sponsor
- Lumosa Therapeutics
- Start
- Aug 2022
- Primary completion
- Dec 2026
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke comparing LT3001 Drug Product with Placebo (2 arms). Primary endpoint: Symptomatic Intracranial Hemorrhage at 24 hours. Started Aug 2022; status: active, not recruiting.
02
Drugs
odatroltide
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05198323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05198323.